Archive · 25 Aug 2026
Mathematical Biology Offers New Strategies Against Cancer Drug Resistance
Professor Philip Maini uses mathematics to understand how cancer cells behave.
His models study how tumours grow and receive oxygen.
They also explore how different cancer treatments might work together.
Some cancer cells can resist medicines and survive treatment.
If all sensitive cells are removed, resistant cells may grow more easily.
Adaptive therapy tries to keep some sensitive cells alive.
These cells can compete with and help control resistant cells.
Mathematical models let researchers compare many treatment plans before testing them with patients.
Maini hopes this work will lead to treatments that improve patient outcomes.
Professor Philip Maini uses mathematical models to study cancer and living systems.
His research examines combination therapies and aims to predict effective chemo/radiotherapy protocols.
The models address angiogenesis, oxygen delivery, cell growth and tumour resistance.
Adaptive therapy maintains drug-sensitive cancer cells to help control resistant cells.
Mathematical modelling allows treatment strategies to be tested more cheaply than clinical trials.
- Who
- Professor Philip Maini, with mathematicians, clinicians and biologists.
- What
- Research using mathematical biology to design cancer therapies and address drug resistance.
- When
- The work was discussed this week on the University of Oxford's PULSE platform; Maini has worked on anti-tumour therapies for several years.
- Where
- The research is associated with the University of Oxford and its Wolfson Centre for Mathematical Biology.
- Why
- To gain biological insights, improve treatment strategies and reduce the risk that resistant tumour cells dominate.
- Researcher
- Professor Philip Maini
- Institution
- University of Oxford
- Research areas
- Angiogenesis, oxygen delivery, cell growth and tumour resistance
- Therapy focus
- Combination cancer therapies and chemo/radiotherapy protocols
- Adaptive therapy
- Maintaining a baseline population of drug-sensitive tumour cells
- Modelling advantage
- Treatment strategies can be compared without the cost and practical limits of clinical testing
- Academic role
- Director of Oxford's Wolfson Centre for Mathematical Biology